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Glucagon and prostaglandins are mediators of amino acid-induced rise
in renal hemodynamics. An oral protein load or infusion of amino acids
induces a rise in renal hemodynamics in normal subjects, but the
mechanisms mediating this phenomenon are unknown. We investigated
whether glucagon may mediate the increase in RPF and GFR induced
by an arginine infusion and whether prostaglandins are required for this
effect. In four different studies, normal subjects underwent 13 inulin and
PAL-I clearances of 30 minutes each. During the fourth and tenth
clearance periods arginine HCI, 250 mg/kg, was infused over 30
minutes. At the beginning of the fifth clearance period several subjects
ingested indomethacin, ISO mg, (N = 8) or ibuprofen. 800 mg, (N = 6).
Control subjects (N = 4) did not receive cyclooxygenase inhibitors. Six
subjects underwent a similar protocol except that they were infused
with glucagon, 6 ng/kg/min, instead of arginine. for 30 minutes during
the fourth and tenth periods. They also ingested indomethacin, 150 mg.
in the fifth period. In all four studies, a transient and significant rise in
RPF and GFR and fall in RVR occurred during the first arginine or
glucagon infusion. These changes in renal hemodynamics were blocked
when the arginine or glucagon infusion was repeated after administra-
tion of indomethacin or ibuprofen. Urinary excretion of 6-keto-PGF1,
did not rise with either arginine infusion in the control subjects or in the
individuals who received indomethacin. As predicted, urinary 6-keto-
PGF1, fell significantly after ingestion of indomethacin before the
second infusion of arginine. Plasma norepinephrine arid epinephrine
concentrations were unaffected by the arginine infusions or by indo-
methacin. These findings suggest that glucagon is a mediator of the
arginine induced rise in RPF and GFR, and that prostaglandins are
necessary for this effect.
It is well documented that the oral intake of protein or the
infusion of amino acids induces an acute rise in renal plasma
flow (RPF) and glomerular filtration rate (GFR) in normal
individuals and most patients with renal disease [1—6]. Two
implications have been drawn from these findings that have
elicited considerable interest. First, it has been inferred that the
increased RPF and GFR after the protein or amino acid load
reflect the maximum potential renal function of the kidney [1, 2,
71. Second, the renal vasodilation and hyperfiltration that occur
acutely after a protein load may be caused by the same
mechanisms by which a persistently high protein intake induces
a chronic increase in RPF, GFR and transcapillary hydraulic
pressure [8—121. Hence, an understanding of the mechanisms by
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which a high protein diet increases RPF and GFR may lead to
a more rational therapy for chronic renal disease.
Since the amino acid-induced increase in renal hemodynam-
ics can be blocked with somatostatin [13—151, this rise is
probably mediated by one or more peptide hormones. Growth
hormone may increase RPF and GFR chronically [16—181, but it
does not seem to have an acute effect on these processes [6, 191.
Glucagon infusions increase RPF and GFR; however, in hu-
mans and animals this effect has largely been shown with
supraphysiological doses of glucagon [15, 20—22] or with mix-
tures of glucagon and other hormones [13]. The present study
was therefore undertaken to examine whether an infusion of
glucagon in quantities that raise plasma hormone levels to
postprandial values will acutely increase RPF and GFR. Since
certain prostaglandin hormones are vasodilators, this study also
investigated whether the effects of an amino acid or glucagon
infusion on RPF and GFR are mediated or modulated by
eicosanoids.
Methods
Subjects and basic protocol
Twenty normal subjects participated in one or more of the
following studies. All were found to be healthy by medical
history, physical examination and routine blood chemistry
measurements; none of the volunteers had a history of renal
disease. Subjects ate self-selected diets prior to participation in
the study. Each individual gave written informed consent as
approved by the Human Subjects Committee at Harbor-UCLA
Medical Center.
Subjects were admitted to the clinical research center at
Harbor-UCLA Medical Center at 7:00 a.m. after 12 hours of
fasting except for ad libitum water intake. They did not receive
any food until the renal function studies were finished. All
individuals were maintained at bedrest throughout the study
except that they used a commode or stood to urinate.
Body weight and height were measured. A butterfly cannula
was inserted into one vein in each forearm. One vein was used
for all infusions; the other vein was used for withdrawal of
blood samples. Between 7:00 and 8:00 a.m., subjects drank 7.0
mI/kg body weight of deionized water. Between 9:00 a.m. and
3:30 p.m., when urine collections were performed, the volun-
teers ingested 200 ml of deionized water every 30 minutes to
maintain a urine flow of 6 to 10 mI/mm. At 8:00 a.m., subjects
received an intravenous bolus injection of 50 mg/kg of inulin
1147
1148 Hirschberg et a!: Amino acid-induced rise in hemodynanics
(American Critical Care, McGaw Park, Illinois, USA) and 8
mglkg of p-aminohippuric acid (PAH, Merck, Sharp and Dohme,
West Point, Pennsylvania, USA). Immediately afterwards, an
intravenous infusion of inulin, 0.5 mg/kg/mm, and PAH, 0.25
mg/kg/mm, in normal saline was initiated. This infusion was
given at a constant rate of 30 ml/hr by infusion pump, and
plasma inulin and PAH levels were maintained at about 25
mg/dl and 2.5 mg/dl, respectively.
After allowing one hour for equilibration, urine was collected
by spontaneous voiding every 30 minutes starting at 9:00 a.m.
Thus, 13 urine collection periods were performed during a 6.5
hour study. The first three collection periods were used for
baseline clearance measurements; the last 10 clearance periods
were carried out after the specific infusion protocols, described
below, were implemented. In all studies, blood was drawn at
the beginning and end of each clearance period in preheparin-
ized tubes for the measurement of hematocrit and plasma inulin
and PAH levels. Plasma concentrations of each compound,
obtained at the beginning and end of each urine collection
period, were averaged for calculating the respective clearances.
Starting with both the fourth and tenth clearance periods (that
is, beginning at 10:30 am. and 1:30 p.m.), 2 ml of blood were
collected on five occasions each, separated by 15 minute
intervals, for measurement of plasma glucagon. The blood was
collected in glass tubes containing 0.2 ml of aprotinin (Trasy 101,
Bayer AG, Leverkusen, FRG). in some studies, starting at
these same two times (that is, 10:30 a.m. and 1:30 p.m.), 2 ml of
blood was collected on four occasions each, separated by 15
minute intervals, for measurement of plasma epinephrine and
norepinephrine. In some studies, one ml of heparinized plasma
was deproteinized with crystalline sulfosalicylic acid and frozen
at —70°C until measured for arginine. An aliquot of the urine,
collected in the periods before and during each arginine infu-
sion, was frozen separately at —70°C for the determination of
urinary 6-keto-PGF1. All of the above blood samples were
drawn on ice and immediately centrifuged. Except as indicated
above, plasma and urine samples were stored at —20°C until the
various measurements were performed.
At the midpoint of each clearance period, blood pressure was
measured with a sphygmomanometer with the subject in a
supine position. The mean arterial blood pressure (MABP) was
estimated from the systolic (SBP) and diastolic (DBP) pressures
as follows:
MABP = (SBP — DBP)/3 + DBP
Specific protocols
Four different studies were performed using the basic proto-
col described above.
Study I (control study). Three men and one woman with a
mean age of 25 years (range, 19 to 34) and body weight of 70.1
kg (range, 54.4 to 88.8) were studied. After the three baseline
clearance periods, subjects received an infusion of 10% arginine
MCI (R-Gene, Cutter Laboratories, Berkeley, California, USA),
250 mg/kg body weight, over 30 minutes during the fourth
clearance period (between 10:30 and 11:00 a.m.). This was
followed by five recovery collection periods. During the tenth
clearance period (1:30 to 2:00 p.m.), exactly the same infusion
was repeated and subjects were then followed for three more
collection periods.
Study 2 (arginine-indo,nethacin-arginine study). Seven men
and one woman were studied using the same protocol as
described in Study 1. Their mean age was 28 years (range, 19 to
44), and mean body weight was 75,9 kg (range, 54.1 to 89.9).
The only difference from Study I was that the subjects received
a single oral dose of 150 mg of indomethacin (Indocin, Merck,
Sharp and Dohme) at 11:30 am., 30 minutes after the first
arginine infusion and two hours before the second arginine
infusion. The same blood and urine collections were performed
as in the first study.
Study 3 (arginine-ihuprofen-arginine study). Four men and
two women were studied. Their mean age was 26 years (range,
19 to 35), and their body weight averaged 71.0 kg (range, 55.3 to
89.1). This study was identical to Study 2 except that the
volunteers received a single oral dose of 800 mg of ibuprofen
(Ibuprofen, Boots Laboratories, Inc., Palisades Park, New
Jersey, USA) instead of indomethacin. The measurements
described in the basic protocol were carried out except that
urinary 6-keto-PGF1a and plasma epinephrine, norepinephrine
and arginine were not determined, since no major differences
from the indomethacin treated group were expected.
Study 4 (glucagon-indo,nethacin-gluc'agon). Four men and
two women with a mean age of 28 years (range, 21 to 32) and
body weight of 70.7 kg (range, 60.6 to 79.7) were studied. Each
subject received by infusion pump a constant infusion of
glucagon (Eli Lilly Co, Indianapolis, Indiana, USA), 6 nglkg/min,
in 18 ml of normal saline over 30 minutes on two occasions,
during the fourth and the tenth clearance periods, respectively.
At the end of the fifth period, at 11:30 a.m., subjects ingested
150 mg of indomethacin. Thus, this protocol was exactly the
same protocol as in Study 2 except that the arginine infusions
were replaced by a constant infusion of a low dose of glucagon.
We selected this particular dose of glucagon after having tried
higher doses in a pilot study; the currently used dose resulted in
an increase in and peak level of plasma glucagon that was very
similar to the rise and peak values of glucagon that occurred
with the infusions of arginine. All measurements described in
Study 3 were performed.
Laboratory analyses
Inulin and PAH concentrations in plasma and urine were
determined with the indole method [23] and diazoreaction [241,
respectively. Plasma glucagon was measured by radioimmuno-
assay using the 04A antiserum (Department of internal Medicine,
University of Texas Health Science Center, Dallas, Texas,
USA). Plasma epinephrine and norepinephrine were deter-
mined as previously described [25]. Plasma arginine levels were
measured with an Automated AminoAcid Analyzer Model
121MB (Beckman Instruments, Fullerton, California, USA).
Hematocrit was measured by the microhematocrit method.
For determination of urinary 6-keto-PGF1 , concentrations,
20 ml of urine were acidified with 1/6 N HCI to a pH of 4.1 to 4.5,
spiked with small known amounts of tritiated 6-keto-PGF1a
(New England Nuclear. Boston, Massachusetts, USA), and
extracted two times with equal volumes of ethylacetate. The
organic phase was dried under nitrogen at 37°C, and the dried
extract was redissolved in 0.2 ml of the mobile phase (acetonitrile-
water-acetic acid-benzine, 30-69.7-0.1-0.2, vol/vol/vol/vol). The
redissolved extract was purified with reverse-phase HPLC
using a 5 micron C-l8 fatty acid analysis column (Waters
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Fig. 1. Renal plasma flow (RPF), glomerular filtration
rate (GFR), total renal vascular resistance (RVR) and
mean arterial blood pressure (MABP) in the control
subjects (0; Study I, N = 4) and the subjects, who
ingested 150 mg/kg indomethacin between the two
arginine HC1 infusions (•; Study 2, N = 8). Arginine
HCI was infused during the time indicated by the
striped bars. Indomethacin was ingested at the time
270 330 390 indicated by the arrow. Significantly different from the
mean value of the two baseline clearance periods that
immediately preceded the infusion: * < 0.05.
Assoc., Milford, Massachusetts, USA). The recovery was 31 to
48%. The peak fractions were combined, and a radioimmuno-
assay was performed using a commercially available 1251
labeled specific antibody (Amersham, Arlington Heights, Illi-
nois, USA). Assay results were corrected for tracer recovery.
For further validation, the HPLC peaks of eight samples were
also measured by another assay [261. Results of the two assays
were similar (r = 0.94). Attempts were also made to measure
prostaglandin E2 in the urine specimens, but br technical
reasons this could not be done.
Calculations
GFR was considered to be equal to the inulin clearance. To
calculate RPF, PAH clearance values were corrected for the
renal extraction of PAH. Since renal vein PAH concentrations
were not measured, we assumed that PAH extraction was 85%
as previously described [271 and as other investigators have
done for normal subjects [281. Hence, RPF CPAH/O.SS. All
clearances and flows are expressed per 1 .73 m2of body surface
area.
Filtration fraction (FF) and total renal vascular resistance
(RVR) were calculated from the following equations:
FF = GFRIRPF;
RVR = MABP/RBF (mm Hg min/l.73 m2/ml);
RBF = RPF/(I — HCT/l00).
Statistical analyses for changes in the repetitive measurements
were carried out by paired t-test. Variance is expressed as
standard error of the mean.
Results
In the control study (Study 1, the arginine-arginine infusions),
during the first arginine infusion, there was a transient rise in
RPF and GFR of +27.6 4.1% (P < 0.05) ) and +22.9 2.2%
(P <0.05), respectively (Fig. 1, Table I). Both values returned
to baseline in the clearance period immediately following the
arginine infusion. When the arginine infusion was repeated in
period 10, RPF and GFR again increased by + 28.5 4.7% (P <
0.05) and +27.1 1.0% (P < 0.01) (Fig. I, Table 1). The
baseline filtration fraction was 0.16 0.01 and did not change
significantly during the study. MABP also did not change
significantly during the course of study (Fig. 1). Total renal
vascular resistance (RVR) decreased by —25.5 3.7% (P <
0.05) and —22.1 3.8% (P < 0.05), respectively, during each of
the arginine infusions and returned to baseline immediately
after each infusion (Fig. 1).
In Study 2 (arginine-indomethacin-arginine), there was a
significant increase in RPF (+25.2 2.5%, P < 0.01) and GFR
(+20.3 2.5%, P < 0.05) and a decrease in RVR (—25.7
3.7%, P < 0.05) during the first arginine infusion (Fig. 1, Table
1). These changes were transient, and values returned to
baseline levels by the first clearance period after cessation of
the infusion.
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Table 1. RPF and GFR before (baseline), during (0—30 win) and after (30—60 win, 60—90 win) the two infusions of arginine or glucagon
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These results stand in contrast to the changes in renal
hemodynamies during the second arginine infusion, after the
indomethacin was ingested. There was no change in RPF (+ 8.4
4.1%, P:NS), GFR (+5.4 4.9%, P:NS), or RVR (—8.3
4.2%, P:NS). However, during the first clearance period after
the second arginine infusion was terminated, GFR tended to
decrease below baseline levels (P:NS); during the next period it
had returned to baseline. This phenomenon was not observed
for RPF (Fig. 1, Table I). Filtration fraction did not change
significantly during this infusion study.
The baseline plasma arginine levels, measured in Studies I
Fig. 2. Renal hemodynamics and mean arterial
blood pressure in i/ic Study 3 sub) ens who ingested
ihuprqfen (N 6). Symbols are defined in the legend
to Figure I. Significantly different from the mean
270 330 390 value of the two baseline clearance periods thatimmediately preceded the infusion: * < 0.05,
<0.01.
and 2, before the first arginine infusion was given, were 85 4
and 70 4 tmol/liter. During the arginine infusion, plasma
concentrations rose to 4349 303 and 4146 225 ttmol/Iiter,
respectively. Plasma arginine did not return to preinfusion
values during the second baseline. Immediately before the
second arginine infusion; the plasma concentrations were 426
49 and 377 39 ttmol/liter, respectively, in Studies I and 2. The
second arginine infusion induced a rise in plasma arginine to
4323 432 and 4617 77 ,amol/liter, respectively, in the two
studies.
Study 3 examined whether another eyelooxygenase inhibitor
First infusion
Study Baseline 0—30
mm
30—60 60—90
Second
Baseline 0—30
infusion win
30—60 60—90
Renal plasma flow mllminl/.73 in2
1 ARG-ARG (Control) 601.7 25.3" 766.9 33.5" 544.8 13.5 552.8 15.9 557.7 18.8 713.3 15.9" 566.8 55.8 582.2 24.7
2 ARG-INDO-ARG 603.4 28.8 753.1 30.l' 616.2 33.2 608.4 21.0 549.2 22.9 596.8 38.3 513.4 22.1 514.5 36.5
3 ARG-IBU-ARG 576.2 40.5 787.4 5704- 596.8 30.0 585.8 42.2 596.3 36.3 685.0 39.5 506.2 + 23.0 577.6 32.9
4 GLIJC-INDO-GLUC 635.7 31.9 774.9 33.3" 657.1 53.1 585.7 32.5 605.0 21.7 657.9 43.4 546.9 -- 26.3 585.9 29.7
Glomerular filtration rate mI/win/i .73w2
I ARGARG (Control) 97.1 3.7 119.4 5.1" 84.2 5.2 87.4 2.2 84.8 + 3.3 111.9 4.34- 91.9 8.7 95.0 + 5.4
2 ARG-INDO-ARG 96.7 2.9 116.3 455 92.8 4.4 97.5 3.5 95.8 3.6 102.8 ÷ 7.5 83.2 5.5 86.6 + 3.9
3 ARG-IBU-ARG 100.0 3.2 118.7 97.7 3.7 96.0 3.9 95.5 3.1 97.0 2.0 84.4 2.! 87.5 2.4
4 GLUC-INDO-GLUC 107.6 4.8 125.4 3.5" 115.7 + 5.9 103.3 5.3 107.4 5.7 111.7 2.9 107.8 9.6 103.1 5.1
Different from the respective baseline measurements: "P < 0.05. 4- P < 0.01.
Mean 5EM.
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Fig. 3. Renal hemodynainics and mean arterial
blood pressure in the subjects who received
glucagon infusions and ingested indomethacin (150
ing) (Study 4, N = 6). Symbols are defined in the
legend to Figure 1. Significantly different from the
390 mean value of the two baseline clearance periods
that immediately preceded the infusion: * < 0.05,
< 0.01.
with a different chemical structure, ibuprofen, could also block
the arginine induced increase in RPF and GFR and decrease in
RVR. During the first arginine infusion in this study, RPF and
GFR rose by +36.8 3.3% (P < 0.01) and + 18.7 2.3% (P <
0.05), respectively (Fig. 2, Table I). After ibuprofen, 800 mg,
was ingested, the arginine infusion did not induce a significant
rise in RPF (+ 15.2 3.4%, P:NS) or GFR (+ 1.9 2.4%,
P:NS). RVR decreased by —28.3 5.8% (P < 0.05) during the
first infusion, but the change during the second infusion, —18.6
8.4%, was not statistically significant. The difference in the
fall in RVR between the two arginine infusions was not signif-
icant (P = 0.283).
In clearance period 5, immediately after the first arginine
infusion was terminated, RPF, GFR and RVR returned to
baseline values. During clearance period 11, immediately after
cessation of the second arginine infusion, RPF and GFR tended
to fall to levels below baseline (—15.1% and —12.0%, respec-
tively), and RVR tended to remain above the baseline (+9.5%)
(Fig. 2, Table 1); however, none of these changes was statisti-
cally significant. During clearance periods 12 and 13, RPF, GFR
and RVR returned progressively to baseline values (Fig. 2).
Filtration fraction and mean arterial blood pressure did not
change significantly during the study.
Study 4 (glucagon-indomethacin-glucagon) was carried out to
assess 1) whether raising plasma glucagon concentrations to the
levels observed after the arginine infusions would increase RPF
and GFR and reduce RVR to the same extent as occurred with
the arginine infusion, and 2) whether this effect of glucagon
could be blocked with an inhibitor of cyclooxygenase. During
the glucagon infusion, there was an increase in RPF and GFR of
+21.9 5.2% (P < 0.01) and +16.5 3.3% (P < 0.05),
respectively (Fig. 3, Table I). RVR decreased by —25.3 5.1%
(P < 0.05). After pretreatment with indomethacin, the second
glucagon infusion did not cause a significant change in RPF,
GFR or RVR (Fig. 3, Table I). Thus, the glucagon induced
changes in RPF, GFR and RVR were blocked by the ingestion
of indomethacin, 150 mg.
During each of the arginine infusions in Studies I to 3, the
plasma glucagon levels rose rapidly, regardless of whether the
subjects were pretreated with a cyclooxygenase inhibitor (Table
2). In Study 4, the rise and maximum plasma glucagon levels
during the two glucagon infusions were virtually identical to the
increase that occurred with the arginine infusions. However,
plasma glucagon fell rapidly to baseline after termination of the
glucagon infusion. In contrast, the decline in plasma glucagon
was slower after cessation of the arginine infusion. This sug-
gests that during the rather slow fall to baseline of plasma
arginine after the arginine infusion, there may have been
continued stimulation of glucagon secretion.
Plasma levels of epinephrine and norepinephrine were not
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Table 2. Plasma glucagon (pg/mi) levels before (baseline, BL) during and after the aiginine or glucagon infusions
First infusion Second infusion
Infusion" After infusion Infusion" After infusion
Study BL 15 mm 30 mm 45 mm 60 mm BL IS mm 30 mm 45 mm 60 mm
IARG-ARG 137 19d 425 83" 584 129" 374 101' 295 95' 148 + 16 433 + 10" 514 70" 360 90" 288 92"
(Control)
2 ARG-INDO- 169 + 20 456 + 95" 662 158b 395 84" 306 82" 254 64 457 90" 567 90" 381 82" 283 66"
ARG
3 ARG-IBU- 169 + 17 415 44" 632 43" 244 28 183 21 152 -4- 28 403 + 57" 603 46" 230 - 49" 144 17
ARU
4 GLUC-INDO- 183 10 476 41" 630 60" 174 14 178 14 174 17 454 7!" 648 86" 184 20 167 ÷ 12
GLUC
Compared to respective baseline P < 0.05. b p < 0.01.
1 Infusions were given from 0 to 30 minutes.
d Mean SEM
Table 4. Urine 6-keto-PGF,,, excretion before (baseline) and during the two arginine infusions in Study 1 and Study 2
Second
First First ARG Second ARG
Study baseline infusion baseline infusion
1
-
ARG-ARG 137.1 27.1 115.1 26.5 109.7 29.6 97.5 21.6
(Control)
2 ARG-INDO-ARG 260.9 60.2
Data are mean SEM.
Compared to first baseline " P < 0.05, 4- P < 0.01
Compared to first arginine infusion " P < 0.05
altered by the arginine or glucagon infusions, nor by indometh-
acm or ibuprofen (Table 3). Similarly, neither the arginine or
glucagon infusions nor the cyclooxygenase inhibitors affected
MABP (Figs. I to 3).
In Study I (control study), the baseline urinary excretion of
6-keto-PGF1a was 137.1 27.1 pg/mm (Table 4). The urinary
excretion of this metabolite did not change significantly during
the first arginine infusion, the subsequent second baseline
measurement, or the second arginine infusion. In Study 2, the
baseline urinary excretion of 6-keto-PGF,1 was greater than in
the Study I patients. During the first arginine infusion in Study
2, the urinary excretion of this metaholite fell significantly, by
19.1 5.3% (P < 0.05). At the second baseline, two hours after
pretreatment with indomethacin, urinary excretion of 6-keto-
PGF1. had fallen further, by 65.1 5.3% of the initial baseline
values (P < 0.05) and by 54.4 4.7% (P < 0.05) of the values
observed during the first arginine infusion (Table 4). During the
second arginine infusion, there was a tendency, not significant,
for urinary 6-keto-PGF14, excretion to fall further. In all of these
studies, the hematocrit did not change significantly during the
arginine or glucagon infusions,
Discussion
The rise in RPF and GFR during the arginine infusion was
similar to the changes observed in other studies in which
individuals received a protein load or an infusion of amino acids
[I, 3—6, 13]. However, the mechanisms which mediate the acute
renal response to a protein or amino acid load are not well
defined. Amino acid infusions are considered a model for
protein loading or ingestion of high protein diets with regard to
their effects on renal perfusion and filtration. We used the single
amino acid arginine, because we have previously characterized
some of the systemic and renal effects of short-term arginine
infusions [6].
Plasma
Study pg/mi
1 ARG-ARG Norepinephrine
Epinephrine"
2 ARG-INDO-
ARG
Norepinephrine
Epinephrine'
Table 3. Plasma norepinephrine and epmnephrine concentrations in response to the two arginine infusions in Study I and Study 2
First arginine infusion Second arginine infusion"
IS mm 30 mm
457 106 518 - 135
42 20
(<20—125) (<20—28)
308÷36 309±43
20 22
(<20—24) (<20—27)
45 mm
530 143
34
(24—36)
321 35
20
(<20—31)
BL
385 99"
33
(<20—51)
291 42
20
(<20—73)
Infusions were given from 0 to 30 minutes.
h Mean SEM.
Results for epinephrinc levels are depicted as median and range since some values were below the detection limit of the assay (20 pg/nil).
BL
452 -'- 123
36
(<20—103)
259 77
22
(<20—58)
IS mm 30 mm 45 mm
433 lOS 448 + III 474 127
29 26 29
(<20—31) (<20—73) (<20—59)
277 71 302 100 266 46
42 32 30
(<20—73) (<20—83) (<20—76)
197.7 38.4" 90.8 l5.54-' 79.8 15.2
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These series of four studies were carried out to further
evaluate the mechanisms responsible for the arginine induced
acute rise in RPF and GFR. Study I, in which normal adults
received a 30 minute intravenous infusion of arginine HCI, 250
mg/kg, on two occasions separated by a 150 minute interval,
was carried out as a control experiment to characterize the
normal response to the intravenous arginine load. During both
infusions, there was a transient rise in RPF and GFR and fall in
RVR; the magnitude of each of these changes was the same in
both infusions. These findings suggest that in Studies 2 through
4, any changes in response to the second arginine HCI infusion
are not due to time dependent factors but are due to the
manipulations carried out between the first and second infu-
sions. Previous studies indicate that the changes in renal
function during arginine HCI infusion are not due to the
osmotic, chloride or acid load [61.
In a previous study we observed that growth hormone does
not play a role in the acute rise in RPF or GFR following an
infusion of arginine HCI [61. During infusion of arginine, pa-
tients with growth hormone deficiency displayed an increase in
RPF and GFR that was similar to normal individuals. More-
over, in the normal individuals, there was no exact temporal
relationship between the increase in plasma growth hormone
with the arginine infusion and the rise in RPF and GFR. This is
in contrast to the response of plasma glucagon which rose
concurrently with the increase in renal hemodynamics in the
normal as well as growth hormone-deficient subjects [6].
Premen and coworkers reported evidence that, in dogs,
glucagon mediates the protein-induced acute rise in RPF and
GFR [15, 29]. Somatostatin blocked the increase in RPF and
GFR following a protein load; this suggests that peptide hor-
mones are mediating factors. When glucagon was infused into a
peripheral vein, RPF and GFR increased only when plasma
glucagon levels rose above the values that are obtained with a
protein load. However, when a small dose of glucagon was
infused into the portal vein of these dogs, RPF and GFR rose.
These studies suggest that plasma glucagon, in postprandial
concentrations, does not act directly on the kidney to increase
renal function but may act through the liver, possibly by
stimulating the release of another humoral factor. This other
factor has been called glomerulopressin [29—31].
Castellino, Coda and DeFronzo demonstrated that in normal
adults who were infused with a mixture of amino acids, the rise
in RPF and GFR could be blocked by somatostatin infusion
[13]. The subjects then received, in addition to the amino acid
and somatostatin infusions, a combined infusion of glucagon,
growth hormone and insulin that raised plasma levels to the
same values observed with the amino acid infusion alone.
Under these circumstances, RPF and GFR rose to the same
magnitude as with the infusion of amino acids alone without
somatostatin. A similar observation was reported by Palmore
who infused alanine, with or without somatostatin, into dogs
[14]. Somatostatin significantly lowered the alanine induced rise
in RPF and GFR. A glucagon infusion of 7 to 11 ng/kg/min
increased RPF and GFR to the same extent as with the alanine
infusion. However, the author did not report the plasma gluca-
gon concentrations that were attained with the alanine or
glucagon infusions. Parving and coworkers demonstrated a
significant rise in RPF and GFR without a change in the
filtration fraction in subjects with insulin-dependent diabetes
mellitus who received glucagon infusions of 10 or 4 ng/kg/niin
[32].
Amid and coworkers infused a mixed amino acid solution
into pancreatectomized patients. In contrast to normal subjects,
RPF and GFR did not increase in these patients [331.
The foregoing studies provide evidence that glucagon is a
mediator of the protein or amino acid induced acute rise in RPF
and GFR. The present study extends these observations by
demonstrating that 1) acute intravenous infusions of small
quantities of glucagon do raise RPF and GFR in humans, and 2)
this effect occurs at plasma glucagon concentrations that may
occur in response to an amino acid load (Study 4, Table 2).
During the glucagon infusion, there was a rise in RPF and GFR
and a fall in RVR which were of similar magnitude to that
observed with the arginine infusion (Table 1). These findings
provide strong evidence that physiological concentrations of
glucagon increase RPF and GFR and lower RVR in humans.
The data do not indicate whether the effect is due to a direct
action of glucagon on the kidney.
In order to assess whether the effect of the amino acid
infusion on RPF and GFR requires the presence of prostaglan-
dins, we carried out Studies 2 and 3 in which the subjects
received cyclooxygenase inhibitors. Indomethacin, an indole
derivative, and ibuprofen, which is derived from propionic acid,
were selected because they have different chemical structures.
Hence, it is more likely that any effect on renal function would
be due to their common action on cyclooxygenase. With each
drug, there was a marked reduction in the arginine induced rise
in RPF and GFR and in the fall in RVR. These findings do not
indicate whether prostaglandins exert a permissive effect on the
changes in renal function or whether there is an elevation in
prostaglandin levels which directly increases RPF and GFR.
This study also does not rule out the possibility that cyclooxy-
genase inhibitors block the arginine or glucagon induced effects
on renal function indirectly, by suppressing extrarenal synthe-
sis of eicosanoid compounds.
It is puzzling that although cyclooxygenase inhibitors sup-
pressed the arginine induced rise in RPF and GFR, the arginine
infusions in the control study and in the studies where it was
given before the administration of the cyclooxygenase inhibi-
tors did not increase the urinary excretion of 6-keto-PGF,
(Table 4). 6-Keto-PGF1 is a stable metabolite of prostacyclin.
Hence, these findings may indicate that prostacyclin does not
play a role in the arginine induced change in renal hemodynam-
ics.
It is possible that other eicosanoids are responsible for
mediating the changes in RPF, GFR and RVR. Alternatively,
the urinary excretion of 6-keto-PGF1 may not necessarily
reflect the concurrent activity of prostacyclin at the site in the
glomerulus where this compound may lower RVR and increase
RPF and GFR. It is noteworthy in this regard that in human
kidney, prostaglandin-endoperoxide synthetase and cyclooxy-
genase have been localized mainly in the tubular, peritubular
and interstitial areas [34]. Thus, if normally there is much
greater synthesis of prostaglandins in the renal tubules, an
increase in the rate of synthesis in the glomeruli may not lead to
significant changes in the urinary excretion of prostaglandin
metabolites. Moreover, the lack of rise in urinary 6-keto-PGF1
also does not rule out the possibility that prostacyclin exerts a
permissive effect on the arginine induced increase in renal
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hemodynamics. In this regard, in Study 2 after the individuals
ingested indomethacin, there was a significant reduction in the
urinary excretion of the PG!2 metabolite before the second
arginine infusion (Table 4). Although the urinary excretion of
6-keto-PGF1 was falling before the indomethacin was ingested,
the magnitude of the decrease was greater after the indometh-
acm treatment.
It would have been helpful if data on the urinary excretion of
PGE2 were available in this study. However, for technical
reasons we were unable to measure PGE7 in the urines of our
subjects. It is pertinent that Ruilope and associates infused
mixed amino acids into humans at a slower rate than was used
in our study and demonstrated a significant rise in urinary PGE2
excretion [351.
Hostetter reported no increase in urinary PGE2 excretion in
normal subjects who ingested a protein load, even though their
RPF and GFR rose [4]. He concluded that prostaglandins were
not likely to be mediators of the vasodilation during protein
loading. However, inhibitors of prostaglandin synthesis were
not used in these studies. Levine and coworkers [36] demon-
strated a significant increase in both GFR and the rate of
glomerular synthesis of PGE2 and 6-keto-PGF,, in rats in
response to an oral protein load.
The finding that indomethacin also blocked the glucagon
induced rise in RPF and GFR and the decrease in RVR
indicates that prostaglandins are necessary for these renal
hemodynamic effects of glucagon. This is consistent with the
hypothesis that an amino acid load stimulates the release of
glucagon which, in turn, increases RPF and GFR, and that this
latter effect requires the active or permissive action of prosta-
glandin compounds.
TerWee and coworkers infused dopamine intravenously into
normal individuals and observed an increase in RPF and GFR
and a decrease in filtration fraction [7]. As in the present study,
these authors did not find a change in filtration fraction when
amino acids were infused. They concluded that catecholamines
increase RPF and GFR by a different mechanism than the
amino acids. In the present study we observed no increase in
plasma norepinephrine and epinephrine concentrations during
the amino acid infusions, and indomethacin had no effect on
these plasma levels. These findings support the observations of
TerWee and coworkers that systemic catecholamines do not
play a role in the amino acid-induced effects on renal hemody-
namics. However, our findings do not exclude the possibility
that renal nerves may exert a mediating effect.
In summary, the present studies provide evidence that pros-
taglandins are modulators of the arginine induced rise in RPF
and GFR. In normal subjects a low-dose infusion of glucagon
which raises plasma glucagon to the same levels as with the
arginine infusion significantly increases renal hemodynamics.
The glucagon induced rise in RPF and GFR can be blocked by
indomethacin. Thus, these studies indicate that glucagon and
prostaglandins are mediators or modulators of the amino acid-
induced changes in renal hemodynamics.
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